Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition
Authors:
- 26 April 2014
- journal article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 121 (11) , 1357-1366
Abstract
Catechol-O-methyltransferase inhibitor addition to levodopa/carbidopa formulations improves motor symptoms and reduces levodopa fluctuations in patients with Parkinson’s disease. Objectives were to investigate the effects of entacapone and tolcapone on plasma behaviour of levodopa, its metabolite 3-O-methyldopa and on motor impairment. 22 patients orally received levodopa/carbidopa first, then levodopa/carbidopa/entacapone and finally levodopa/carbidopa plus tolcapone within a 4.5 h interval twice. Maximum concentration, time to maximum level and bioavailability of levodopa did not differ between all conditions each with 200 mg levodopa application as a whole. Catechol-O-methyltransferase inhibition caused less fluctuations and higher baseline levels of levodopa after the first intake and less 3-O-methyldopa appearance. The maximum levodopa concentrations were higher after the second levodopa intake, particularly with catechol-O-methyltransferase inhibition. The motor response to levodopa was better with catechol-O-methyltransferase inhibition than without, tolcapone was superior to entacapone. More continuous levodopa brain delivery and lower 3-O-methyldopa bioavailability caused a better motor response during catechol-O-methyltransferase inhibition.Keywords
This publication has 22 references indexed in Scilit:
- Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson DiseaseClinical Neuropharmacology, 2013
- The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrationsEuropean Journal of Clinical Pharmacology, 2011
- Entacapone to tolcapone switch: Multicenter double‐blind, randomized, active‐controlled trial in advanced Parkinson's diseaseMovement Disorders, 2007
- Impact of Gastric Emptying on Levodopa Pharmacokinetics in Parkinson Disease PatientsClinical Neuropharmacology, 2006
- Levodopa and the Progression of Parkinson's DiseaseNew England Journal of Medicine, 2004
- Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson??s DiseaseClinical Pharmacokinetics, 2002
- Long-Term Comparative Experience with Tolcapone and Entacapone in Advanced Parkinson's DiseaseClinical Neuropharmacology, 2001
- Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjectsNaunyn-Schmiedeberg's Archives of Pharmacology, 1999
- Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s DiseaseEuropean Neurology, 1997
- 3‐O‐Methyldopa and the response to levodopa in Parkinson's diseaseAnnals of Neurology, 1987